Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of intralymphatic grass pollen immunotherapy versus placebo
2020-001060-28Phase 3Completed
- Sponsor
- Aarhus University
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) comparing Alutard SQ Phleum pratense intralymphatic immunotherapy with Placebo (2 arms). Started Mar 2021; status: completed.
02
Drugs
alutard phleum pratense
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2020-001060-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001060-28.